A NOVEL AND SELECTIVE RADIOSENSITIZING AGENT FOR PROVIDING MECHANISM- BASED RADIOSENSITIZING EFFECTS IN PROSTATE CANCER

摘要

The present invention provides radiosensitizing effects of silibinin for cancer therapy in relevant in-vitro and pre-clinical mouse models. Novel and selective radiosensitizer in combination with lower doses of radiation achieves desired tumor growth inhibition and preferential radiosensitization to cancer cells and protects normal cells/tissues from radiation toxicity. Radiosensitization mechanism involves inhibition of nuclear EGFR associated DNA repair. Thus the present invention provides a radiosensitizer prepared from a plant flavonoid for preventing the nuclear translocation of EGFR in response to ionizing radiation and subsequent inhibition of DNA repair signaling. The silibinin dose according to the present invention can be realized in patients undergoing radiotherapy for prostate cancer, which underlines the translational significance of the invention.